Supplementary Figure S7 from Human Tumor–Associated Macrophages and Neutrophils Regulate Antitumor Antibody Efficacy through Lethal and Sublethal Trogocytosis

Supplementary Figure S7. (A) Cumulative flow cytometry results showing the ability of blood and tumor FcR+ effectors to kill PKH-67+A431 tumor cells in the presence of nonspecific human IgG1 or IgA2 isotype control Abs (1ug/ml) at a 2:1 E:T ratio in a 12 hrs FACS-based assay. (B and C) Cumulative results showing the kinetics of GFP+A431 tumor cell growth when co-cultured with blood and tumor FcR+ effectors for 48 hrs at a 2:1 E:T ratio in the presence of IgG1 or IgA2 isotype control Abs (1ug/ml) in the IncuCyte® Live Cell Analysis System. (D) Cumulative flow cytometry results showing the ability of blood and tumor FcR+ effectors to kill PKH-67+A549 tumor cells in the presence of nonspecific human IgG1 or IgA2 isotype control Abs (1ug/ml) at a 50:1 E:T ratio in a 12 hrs FACS-based assay. (E and F) Cumulative results showing the kinetics of GFP+A549 tumor cell growth when co-cultured with blood and tumor FcR+ effectors for 48 hrs at a 50:1 E:T ratio in the presence of IgG1 or IgA2 isotype control Abs (1ug/ml) in the IncuCyte® Live Cell Analysis System. All comparisons used one-way ANOVA with Dunnett’s multiple comparisons test. All Data are represented as mean ± SEM. Indicated FcR+ effectors were freshly isolated for all experiments.